Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma

Ji Hun Song, Jeong Hun Bae, Mi I. Rho, Sungchul Lee

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

PURPOSE:: The purpose of this study was to evaluate the effect of intravitreal injection of bevacizumab on subretinal fluid associated with choroidal osteoma. METHODS:: In this retrospective noncomparative case series, eyes with serous retinal detachment involving the macula were treated with intravitreal injection of bevacizumab (1.25 mg/0.05 mL) and carefully followed-up with complete ophthalmic examination, including angiography and optical coherence tomography. The changes in best-corrected visual acuity and central foveal thickness were assessed by optical coherence tomography. RESULTS:: Six eyes received intravitreal injection of bevacizumab for serous retinal detachment. Only one eye had choroidal neovascularization associated with serous retinal detachment. The mean number of injections for the 6 eyes was 2.0 during the mean follow-up period of 11.3 months. The median logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.70 (Snellen equivalent, 20/100) at baseline to 0.30 (Snellen equivalent, 20/40; P = 0.043) at the final visit. The optical coherence tomography result also showed a significant reduction in central foveal thickness with a median central foveal thickness of 357.0 μm at baseline and 169.50 μm at the final visit (P = 0.028). The treatment was well tolerated, without ocular or systemic adverse events. CONCLUSION:: Intravitreal injection of bevacizumab for serous retinal detachment secondary to choroidal osteoma resulted in both visual and anatomical improvements.

Original languageEnglish
Pages (from-to)945-951
Number of pages7
JournalRetina
Volume30
Issue number6
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Subretinal Fluid
Osteoma
Intravitreal Injections
Retinal Detachment
Optical Coherence Tomography
Visual Acuity
Choroidal Neovascularization
Bevacizumab
Angiography
Injections

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Song, Ji Hun ; Bae, Jeong Hun ; Rho, Mi I. ; Lee, Sungchul. / Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma. In: Retina. 2010 ; Vol. 30, No. 6. pp. 945-951.
@article{6703949fdce444c680ec6ed2e1bd9a7a,
title = "Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma",
abstract = "PURPOSE:: The purpose of this study was to evaluate the effect of intravitreal injection of bevacizumab on subretinal fluid associated with choroidal osteoma. METHODS:: In this retrospective noncomparative case series, eyes with serous retinal detachment involving the macula were treated with intravitreal injection of bevacizumab (1.25 mg/0.05 mL) and carefully followed-up with complete ophthalmic examination, including angiography and optical coherence tomography. The changes in best-corrected visual acuity and central foveal thickness were assessed by optical coherence tomography. RESULTS:: Six eyes received intravitreal injection of bevacizumab for serous retinal detachment. Only one eye had choroidal neovascularization associated with serous retinal detachment. The mean number of injections for the 6 eyes was 2.0 during the mean follow-up period of 11.3 months. The median logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.70 (Snellen equivalent, 20/100) at baseline to 0.30 (Snellen equivalent, 20/40; P = 0.043) at the final visit. The optical coherence tomography result also showed a significant reduction in central foveal thickness with a median central foveal thickness of 357.0 μm at baseline and 169.50 μm at the final visit (P = 0.028). The treatment was well tolerated, without ocular or systemic adverse events. CONCLUSION:: Intravitreal injection of bevacizumab for serous retinal detachment secondary to choroidal osteoma resulted in both visual and anatomical improvements.",
author = "Song, {Ji Hun} and Bae, {Jeong Hun} and Rho, {Mi I.} and Sungchul Lee",
year = "2010",
month = "6",
day = "1",
doi = "10.1097/IAE.0b013e3181c720ca",
language = "English",
volume = "30",
pages = "945--951",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma. / Song, Ji Hun; Bae, Jeong Hun; Rho, Mi I.; Lee, Sungchul.

In: Retina, Vol. 30, No. 6, 01.06.2010, p. 945-951.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma

AU - Song, Ji Hun

AU - Bae, Jeong Hun

AU - Rho, Mi I.

AU - Lee, Sungchul

PY - 2010/6/1

Y1 - 2010/6/1

N2 - PURPOSE:: The purpose of this study was to evaluate the effect of intravitreal injection of bevacizumab on subretinal fluid associated with choroidal osteoma. METHODS:: In this retrospective noncomparative case series, eyes with serous retinal detachment involving the macula were treated with intravitreal injection of bevacizumab (1.25 mg/0.05 mL) and carefully followed-up with complete ophthalmic examination, including angiography and optical coherence tomography. The changes in best-corrected visual acuity and central foveal thickness were assessed by optical coherence tomography. RESULTS:: Six eyes received intravitreal injection of bevacizumab for serous retinal detachment. Only one eye had choroidal neovascularization associated with serous retinal detachment. The mean number of injections for the 6 eyes was 2.0 during the mean follow-up period of 11.3 months. The median logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.70 (Snellen equivalent, 20/100) at baseline to 0.30 (Snellen equivalent, 20/40; P = 0.043) at the final visit. The optical coherence tomography result also showed a significant reduction in central foveal thickness with a median central foveal thickness of 357.0 μm at baseline and 169.50 μm at the final visit (P = 0.028). The treatment was well tolerated, without ocular or systemic adverse events. CONCLUSION:: Intravitreal injection of bevacizumab for serous retinal detachment secondary to choroidal osteoma resulted in both visual and anatomical improvements.

AB - PURPOSE:: The purpose of this study was to evaluate the effect of intravitreal injection of bevacizumab on subretinal fluid associated with choroidal osteoma. METHODS:: In this retrospective noncomparative case series, eyes with serous retinal detachment involving the macula were treated with intravitreal injection of bevacizumab (1.25 mg/0.05 mL) and carefully followed-up with complete ophthalmic examination, including angiography and optical coherence tomography. The changes in best-corrected visual acuity and central foveal thickness were assessed by optical coherence tomography. RESULTS:: Six eyes received intravitreal injection of bevacizumab for serous retinal detachment. Only one eye had choroidal neovascularization associated with serous retinal detachment. The mean number of injections for the 6 eyes was 2.0 during the mean follow-up period of 11.3 months. The median logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.70 (Snellen equivalent, 20/100) at baseline to 0.30 (Snellen equivalent, 20/40; P = 0.043) at the final visit. The optical coherence tomography result also showed a significant reduction in central foveal thickness with a median central foveal thickness of 357.0 μm at baseline and 169.50 μm at the final visit (P = 0.028). The treatment was well tolerated, without ocular or systemic adverse events. CONCLUSION:: Intravitreal injection of bevacizumab for serous retinal detachment secondary to choroidal osteoma resulted in both visual and anatomical improvements.

UR - http://www.scopus.com/inward/record.url?scp=77953340792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953340792&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181c720ca

DO - 10.1097/IAE.0b013e3181c720ca

M3 - Article

C2 - 20531145

AN - SCOPUS:77953340792

VL - 30

SP - 945

EP - 951

JO - Retina

JF - Retina

SN - 0275-004X

IS - 6

ER -